$-0.07 EPS Expected for Organovo Holdings, Inc. (ONVO)

May 17, 2018 - By Hannah Black

Organovo Holdings, Inc. (NASDAQ:ONVO) LogoInvestors sentiment decreased to 0.67 in 2017 Q4. Its down 0.86, from 1.53 in 2017Q3. It turned negative, as 16 investors sold Organovo Holdings, Inc. shares while 38 reduced holdings. 18 funds opened positions while 18 raised stakes. 20.74 million shares or 13.74% less from 24.05 million shares in 2017Q3 were reported.
Bnp Paribas Arbitrage has invested 0% in Organovo Holdings, Inc. (NASDAQ:ONVO). Deltec Asset Mngmt Limited Liability Corp stated it has 10,000 shares or 0% of all its holdings. Private Advisor Grp Limited Liability Corp has invested 0% in Organovo Holdings, Inc. (NASDAQ:ONVO). Jefferies Grp Inc Ltd Liability Corporation holds 0% or 27,100 shares. Amalgamated Comml Bank holds 13,552 shares or 0% of its portfolio. Alliancebernstein Limited Partnership accumulated 80,350 shares. 1.17 million were accumulated by Northern Trust. Group One Trading Limited Partnership reported 0% in Organovo Holdings, Inc. (NASDAQ:ONVO). Tortoise Invest Management Ltd Liability Company invested in 0% or 360 shares. Raymond James & holds 0% of its portfolio in Organovo Holdings, Inc. (NASDAQ:ONVO) for 30,974 shares. Moreover, Messner & Smith Theme Value Investment Mgmt Limited Ca has 0.06% invested in Organovo Holdings, Inc. (NASDAQ:ONVO) for 30,025 shares. Lehman Finance Resource reported 161,000 shares. Tiaa Cref Inv Limited Liability Corp has 228,840 shares for 0% of their portfolio. Lmr Ptnrs Limited Liability Partnership reported 0% of its portfolio in Organovo Holdings, Inc. (NASDAQ:ONVO). Paloma Mngmt holds 97,292 shares or 0% of its portfolio.

Analysts expect Organovo Holdings, Inc. (NASDAQ:ONVO) to report $-0.07 EPS on June, 6.They anticipate $0.03 EPS change or 30.00 % from last quarter’s $-0.1 EPS. After having $-0.07 EPS previously, Organovo Holdings, Inc.’s analysts see 0.00 % EPS growth. The stock increased 2.35% or $0.04 during the last trading session, reaching $1.74. About 1.28 million shares traded or 36.14% up from the average. Organovo Holdings, Inc. (NASDAQ:ONVO) has declined 67.42% since May 17, 2017 and is downtrending. It has underperformed by 78.97% the S&P500.

Organovo Holdings, Inc., an early commercial stage company, creates and creates functional and three-dimensional human tissues for use in medical research and therapeutic applications. The company has market cap of $192.86 million. The firm develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic, and other partners. It currently has negative earnings. The Company’s 3D human tissues could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs.

More important recent Organovo Holdings, Inc. (NASDAQ:ONVO) news were published by: Globenewswire.com which released: “Organovo to Present at 2nd Annual NASH Summit” on April 24, 2018, also Globenewswire.com published article titled: “New Research Coverage Highlights Tyson Foods, Windstream, Laredo Petroleum, Idera Pharmaceuticals …”, Nasdaq.com published: “Organovo Announces Release Date for Fiscal Fourth-Quarter 2018 Financial Results” on May 14, 2018. More interesting news about Organovo Holdings, Inc. (NASDAQ:ONVO) was released by: Globenewswire.com and their article: “Organovo and Samsara Sciences Partner with New Manufacturing USA Institute” with publication date: May 03, 2018.

Organovo Holdings, Inc. (NASDAQ:ONVO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: